Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance

Department of Pathology, Dokuz Eylul University School of Medicine, Izmir, Turkey.
Journal of Gynecologic Oncology (Impact Factor: 2.49). 06/2011; 22(2):89-96. DOI: 10.3802/jgo.2011.22.2.89
Source: PubMed


To determine matrix metalloproteinase-2 and survivin expressions in endometrial cancers, their relation to clinical and histologic parameters and to investigate any difference in the expression of these markers between endometrioid and nonendometrioid cancers.
Ninety-five patients with endometrial cancer, were included. Matrix metalloproteinase-2 and survivin expressions were analyzed immunohistochemically from paraffin-embedded tissues by using specific monoclonal antibodies.
Survivin nuclear expression was higher in endometrioid cancer as compared to nonendometrioid cancer (p=0.040), but there was no difference for cytoplasmic survivin and matrix metalloproteinase-2 expressions between type I and type II carcinomas. Survivin cytoplasmic staining was significantly lower in patients with deep myometrial invasion (p=0.038). Nuclear expression of survivin is decreased in histologic grade 3 tumors compared to grade 1 and 2 tumors (p=0.013), but there is no difference between grade 1 and 2. We did not find any statistically significant difference between survivin or matrix metalloproteinase-2 expressions and survival.
Survivin and matrix metalloproteinase-2 are present in endometrioid and nonendometrioid cancers. Grade 1 and 2 tumors and carcinomas having myometrial invasion less than 50% have higher survivin expression. These results supports that, survivin may play an important role in early stage tumors and early phases of tumor development. We did not find any association between matrix metalloproteinase-2 expression and classical prognostic factors in endometrial cancer and both proteins were not associated with survival.

Download full-text


Available from: Ugur Saygili,
  • [Show abstract] [Hide abstract]
    ABSTRACT: In den letzten Jahren haben zahlreiche Studien prognostische und prädiktive Parameter analysiert, die auch beim Endometriumkarzinom (EC) die operative und adjuvante Therapie zunehmend patientinnen- und tumoradaptiert gestalten. Therapeutisch relevant sind das klinische FIGO-Stadium, der histologische Tumortyp, das Grading, eine Zervixbeteiligung und der Nachweis einer lymphogenen Metastasierung. Neben diesen Faktoren haben auch der Nachweis einer Lymphgefäßinfiltration, die operative Radikalität, Alter und Adipositas prognostische Relevanz. Das Verständnis für die Pathogenese auf molekularer Ebene ist entscheidend für die Identifikation neuer prognoserelevanter Biomarker. Neue tumorbiologische Parameter und Genexpressionsanalysen identifizieren bereits verschiedene Typen beim endometroiden Adenokarzinom mit unterschiedlicher Prognose, jedoch reichen die Daten noch nicht für den klinischen Einsatz.
    Der Onkologe 10/2012; 18(10). DOI:10.1007/s00761-012-2289-8 · 0.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Matrix metalloproteinases (MMPs) are considered as mediators of metastases which may be associated with gynecological cancer survival. However, such relationship remains inconclusive. We carried out the present metaanalysis to evaluate the prognostic value of MMP-2 and MMP-9 in gynecological cancers. Methods: We searched 2 medical databases (Medline and Embase) and located 13 studies with 1841 patients that evaluated the relationship between MMP-2 and MMP-9 and 5-year survival. Risk ratio (RR) with 95% confidence intervals (95% CI) synthesized by random effect model were used to assess the strength of the association. Publication bias was evaluated by Begg-Mazumdar test and Egger's regression test. Results: Mortality was 1.53-fold higher in patients whose tumor cells were positive for MMP-2 (RR 1.53; 95% CI 1.03-2.27; p=0.03).Funnel plot was symmetrical (p=0.721 for Begg-Mazumdar test, and p=0.718 for Egger's regression test). Between-study heterogeneity was significant (p<0.001). Mortality was 1.26-fold higher in MMP-9 positive than negative patients, but without statistical difference (RR 1.26; 95% CI 0.94-1.68; p=0.12). Funnel plot was asymmetrical (p=0.024 for Begg-Mazumdar test). Conclusion: MMP-2 positivity in tumor cells is associated with worse survival in patients with gynecological cancers. Standardization of MMP positivity is needed.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2013; 18(1):202-10. · 0.74 Impact Factor